IIIV vs TYRA

i3 Verticals, Inc.

(IIIV) offers the better valuation at 39. 3x trailing P/E (19. 5x forward), making it the more compelling value choice. Analysts rate i3 Verticals, Inc. (IIIV) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tyra Biosciences, Inc.

(TYRA) delivered a total return of +30. 0%, compared to -29. 1% for i3 Verticals, Inc. (IIIV). Over 10 years, the gap is even starker: TYRA returned +30. 0% versus IIIV's +19. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tyra Biosciences, Inc.

(TYRA) is the lower-risk stock at 0. 75β versus i3 Verticals, Inc. 's 0. 92β — meaning IIIV is approximately 22% more volatile than TYRA relative to the S&P 500. On balance sheet safety, i3 Verticals, Inc. (IIIV) carries a lower debt/equity ratio of 1% versus 2% for Tyra Biosciences, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Tyra Biosciences, Inc.

grew EPS -33. 1% year-over-year, compared to -87. 9% for i3 Verticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

i3 Verticals, Inc.

(IIIV) is the more profitable company, earning 8. 4% net margin versus 0. 0% for Tyra Biosciences, Inc. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIIV leads at 1. 9% versus 0. 0% for TYRA. At the gross margin level — before operating expenses — IIIV leads at 55. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for TYRA: 49.

4% to $50. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Tyra Biosciences, Inc.

(TYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Both have compounded well over 10 years (TYRA: +30. 0%, IIIV: +19. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IIIV (Technology) and TYRA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.